The Financial Express3d
USFDA issues warning of serious allergic reaction with multiple sclerosis drugs; Urges patients to be cautious
Patients should stop taking glatiramer acetate and seek immediate medical attention by going to an emergency room or calling ...
The American Journal of Managed Care4d
FDA Warns of Severe Allergic Reactions With Certain Multiple Sclerosis Drugs
The FDA issued a boxed warning for anaphylaxis risk linked to Glatiramer acetate and Glatopa, used in MS treatment.
GlobalData on MSN3d
FDA adds boxed warning to multiple sclerosis drugs after anaphylaxis cases
Teva Pharmaceutical’s Copaxone was approved by the FDA in 1996 to treat relapsing forms of MS, an autoimmune disorder that ...
Healio4d
FDA issues anaphylaxis warning on multiple sclerosis treatment
The FDA has advised health care professionals and patients with multiple sclerosis that treatment with glatiramer acetate is ...
Monthly Prescribing Reference4d
FDA: Anaphylaxis Risk Prompts Boxed Warning for MS Drug
Reports of anaphylaxis associated with the use of glatiramer acetate have prompted the Food and Drug Administration (FDA) to add a Boxed Warning to the prescribing information.
The Pharma Letter4d
FDA warns of rare but serious allergic reaction with glatiramer
The US Food and Drug Administration (FDA) is warning about the risk of a rare but serious allergic reaction with the medicine ...
Managed Healthcare Executive4d
FDA Adds Boxed Warning to MS Drug Copaxone
Regulatory officials have identified 82 cases worldwide from the FDA Adverse Event Reporting System of anaphylaxis associated ...
FDA Warns Of Severe Allergic Reaction Risk With Teva's Multiple Sclerosis Drug
FDA issues new warnings about rare but severe allergic reactions, including anaphylaxis, linked to MS drug glatiramer acetate, urging immediate medical attention.